Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902252 · ClinicalTrials.gov registry record · Phase 3
Multi-National Phase III Vitala™ 12-Hour Wear Test
A Phase 3 study, sponsored by ConvaTec.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00902252: Completed Phase 3 study, sponsored by ConvaTec.
NCT00902252 is a Phase 3 study that has completed, run by ConvaTec. The registered enrollment target is 78 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00902252, a Phase 3 study, has completed, sponsored by ConvaTec.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to demonstrate that the Vitala™ Continence Control Device is both safe and effective when worn up to 12 hours per day.
Primary Outcome
Will be assessed by measuring the frequency of adverse events relating to the stoma (including gastrointestinal, stomal and surrounding skin events), microbiology profile and stomal vascularity.
Interventions
- DEVICE Usual
- DEVICE Natura®
- DEVICE Vitala™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
What the finished NCT00902252 record still lists
NCT00902252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Usual is the first listed.
NCT00902252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00902252 about?
NCT00902252 is a clinical study titled "Multi-National Phase III Vitala™ 12-Hour Wear Test". The purpose of this clinical study is to demonstrate that the Vitala™ Continence Control Device is both safe and effective when worn up to 12 hours per day.
What is the current status of trial NCT00902252?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2009-04. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00902252?
The interventions under investigation include: Usual (DEVICE), Natura® (DEVICE), Vitala™ (DEVICE).
Who is sponsoring clinical trial NCT00902252?
This trial is sponsored by ConvaTec, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00902252's enrollment target sits among peer trials
78 1769th of 2000 higher than 230 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia